These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 24726630)

  • 41. Chronic kidney disease-mineral and bone disorder KDIGO guidelines.
    Khwaja A
    Nephron Clin Pract; 2010; 116(1):c25-6. PubMed ID: 20460936
    [No Abstract]   [Full Text] [Related]  

  • 42. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone mineral density in patients with predialysis chronic kidney disease.
    Aggarwal HK; Jain D; Yadav S; Kaverappa V
    Ren Fail; 2013 Sep; 35(8):1105-11. PubMed ID: 23879438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of CKD-MBD targeting the parathyroid gland].
    Isozaki Y; Komaba H
    Clin Calcium; 2016 Jun; 26(6):895-903. PubMed ID: 27230846
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification and management of chronic kidney disease complications by internal medicine residents: a national survey.
    Agrawal V; Agarwal M; Ghosh AK; Barnes MA; McCullough PA
    Am J Ther; 2011 May; 18(3):e40-7. PubMed ID: 19918169
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Updates in CKD-Associated Osteoporosis.
    Khairallah P; Nickolas TL
    Curr Osteoporos Rep; 2018 Dec; 16(6):712-723. PubMed ID: 30353319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Teriparatide:benefit and safety for bone disease in CKD patients undergoing hemodialysis].
    Yamamoto S; Ei I; Narita I
    Clin Calcium; 2016 Sep; 26(9):1301-7. PubMed ID: 27561345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone Disorders in Chronic Kidney Disease: An Update in Diagnosis and Management.
    Babayev R; Nickolas TL
    Semin Dial; 2015; 28(6):645-53. PubMed ID: 26332760
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications.
    Bover J; Ureña-Torres P; Laiz Alonso AM; Torregrosa JV; Rodríguez-García M; Castro-Alonso C; Górriz JL; Benito S; López-Báez V; Lloret Cora MJ; Cigarrán S; DaSilva I; Sánchez-Bayá M; Mateu Escudero S; Guirado L; Cannata-Andía J
    Nefrologia (Engl Ed); 2019; 39(3):227-242. PubMed ID: 30797619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management.
    Cannata-Andía JB; Martín-Carro B; Martín-Vírgala J; Rodríguez-Carrio J; Bande-Fernández JJ; Alonso-Montes C; Carrillo-López N
    Calcif Tissue Int; 2021 Apr; 108(4):410-422. PubMed ID: 33190187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment.
    Haarhaus M; Evenepoel P; ;
    Kidney Int; 2021 Sep; 100(3):546-558. PubMed ID: 34102219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bone Fragility Fractures in CKD Patients.
    Pimentel A; Ureña-Torres P; Bover J; Luis Fernandez-Martín J; Cohen-Solal M
    Calcif Tissue Int; 2021 Apr; 108(4):539-550. PubMed ID: 33219822
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.
    Iwasaki Y; Kazama JJ; Fukagawa M
    Biomed Res Int; 2017; 2017():3485785. PubMed ID: 28421193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is there a role for bisphosphonates in chronic kidney disease?
    Miller PD
    Semin Dial; 2007; 20(3):186-90. PubMed ID: 17555478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effects of SERMs on bone health. The potential of SERM in the care of chronic kidney disease-mineral bone and disorders].
    Hamano T
    Clin Calcium; 2010 Mar; 20(3):373-9. PubMed ID: 20190367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fighting the fracture cascade: evaluation and management of osteoporotic fractures.
    Sack F
    Postgrad Med; 2008 Nov; 120(4):51-7. PubMed ID: 19020365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A rational guide to reducing fracture risk in dialysis patients.
    Toussaint ND; Elder GJ; Kerr PG
    Semin Dial; 2010; 23(1):43-54. PubMed ID: 20331818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone biopsy: an ally in the management of fragility fractures in chronic kidney disease.
    Aguiar F; Meng C; Pereira L; Brito I; Frazão JM
    Acta Reumatol Port; 2018; 43(3):201-209. PubMed ID: 30414368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Osteoporosis management in patient with renal function impairment.
    Lima GA; Paranhos Neto Fde P; Pereira GR; Gomes CP; Farias ML
    Arq Bras Endocrinol Metabol; 2014 Jul; 58(5):530-9. PubMed ID: 25166044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts.
    Delanaye P; Souberbielle JC; Lafage-Proust MH; Jean G; Cavalier E
    Nephrol Dial Transplant; 2014 May; 29(5):997-1004. PubMed ID: 23868144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.